Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the Aerobika* oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1
For people recovering from an acquired or traumatic brain injury, swallowing rehabilitation can be especially challenging because they may experience a period of post-traumatic amnesia. This can limit their ability to form new memories, making it difficult to learn the swallowing exercises that may help them eat again.
May 1, 2018: Today is the 20th annual World Asthma Day, an event held each May to raise awareness of Asthma worldwide. World Asthma Day is organized by the Global Initiative for Asthma, or GINA (www.ginasthma.org), a World Health Organization collaborative and 501(c)3 organization founded in 1993.
A real-world study in more than 18,000 patients has demonstrated superior asthma control with the AeroChamber Plus* Flow-Vu* Anti-Static Valved Holding Chamber (VHC) compared with other chambers.1
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control.
Trudell Medical UK Ltd (TM-UK) is now the UK distributor for the full AeroChamber Plus* range of Valved Holding Chambers (VHCs)
Starting January 1st, 2018, under the new OHIP+ program, the Ontario Drug Benefit Program will cover AeroChamber Plus* Flow-Vu* chambers for children 12 years of age and under. Children prescribed a Metered Dose Inhaler (MDI) for their asthma will now be eligible for one (1) chamber per year under this new program.
A landmark real-world study of more than 18,000 patients has demonstrated superior asthma control with the AeroChamber Plus* Flow-Vu* antistatic Valved Holding Chamber (VHC, or spacer) compared with other chamber devices.1 For those with asthma, particularly children, the choice of device to deliver their medication is an important considerat
Aerobika* device proves to be a cost-effective treatment option in the management of post-exacerbation COPD patients.